Earnings Preview For Inhibikase Therapeutics
Portfolio Pulse from Benzinga Insights
Inhibikase Therapeutics (NASDAQ:IKT) is scheduled to release its quarterly earnings report on Tuesday, 2023-11-14, with an expected EPS of $-1.19. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, the company's stock price has been sensitive to earnings performance and guidance. Last quarter, IKT missed the EPS estimate by $0.19, resulting in a 6.02% share price drop the following day. Over the last 52 weeks, IKT shares have declined by 76.34%, indicating a bearish sentiment among long-term shareholders.
November 13, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Inhibikase Therapeutics is expected to report a quarterly EPS of $-1.19. Past earnings misses have led to significant stock price drops. Long-term shareholders may be bearish due to a 76.34% decline over the past year.
Given the historical sensitivity of IKT's stock price to earnings performance and the significant past year decline, a negative earnings report could likely lead to a further decrease in stock price. However, positive guidance could mitigate this impact.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100